GEORGIA BIO HOSTS 2020 LIFE SCIENCES DAY AT THE STATE CAPITOL

Georgia Bio celebrated the life sciences industry at the Georgia State Capitol February 25, 2020. Georgia Bio’s annual Capitol Day is the chance for members to showcase their innovative products, services, and discoveries at the Georgia State Capitol in Atlanta. The event gives members the chance to meet one-on-one with Georgia’s policymakers. The overall mission of the event is to present to the Georgia General Assembly Georgia Bio’s legislative agenda and vision for life sciences economic growth.

During the day at the Georgia State Capitol, Georgia Bio had over thirty members in attendance focused on discussing with legislatures workforce & talent initiatives, patient access to care, and the creation of a Georgia Rare Disease Advisory Council. Below are a breakdown of the issues and what Georgia Bio supports.

To commend Georgia Bio and recognize February 25, 2020 as the Georgia Life Sciences day at the State Capitol, Governor Brian Kemp declared a Proclamation, Representative Robert Dickey (R – Musella) sponsored House Resolution 1056 and Senator John Wilkinson (R-Toccoa) sponsored Senate Resolution 674. Georgia Bio received special recognition on the Georgia House of Representatives chamber floor and Georgia Senate gallery.

Left to right (Rep. Terry England, Rep. Randy Nix, Phil Gibson, Rep. Robert Dickey, Kristin Boscan, Maria Thacker-Goethe, Speaker of the House Rep. David Ralston)

Presenters at our breakfast reception included:

  • Senator John Wilkinson (R – Toccoa), Chairman Agriculture and Consumer Affairs Committee
  • Senator Dean Burke (R – Bainbridge), Vice-Chairman Health & Human Services Committee
  • Senator Larry Walker (R – Perry), Member Health & Human Services Committee
  • Representative Robert Dickey (R – Musella), Chairman Appropriations Education Subcommittee
  • Representative Butch Parrish (R – Swainsboro), Chairman Appropriations Health Subcommittee
  • Maria Thacker-Goethe, President & CEO, Georgia Bio
  • Kallarin Mackey, Georgia Bio Policy & Advocacy Committee Chair & Director of State Affairs for Emory University
  • Phil Gibson, Ph.D., Georgia BioEd Chairman & Director, Georgia Bioscience Training Center, Quick Start
  • Andy Freeman, Georgia Government Relations Director, American Cancer Society

Georgia Bio gives a special thank you to Governor Brian Kemp, Rep. Robert Dickey & Senator John Wilkinson for sponsoring resolutions, and all the guest speakers and members for joining us in celebrating and showcasing their support to advance the life sciences industry in Georgia! Thank you to our event sponsors, Biotechnology Innovation Organization (BIO), AdvaMed, and UCB.

Workforce & Talent Initiatives:
The life science industry continues to fuel breakthrough discoveries that are having profound impacts around the globe. The life science sector in Georgia grew by 14.9% over the last decade. This high-paying and innovative sector is rapidly changing and the demand for new technical skills is on the rise, especially in Georgia. The industry routinely reports shortages of employees with the necessary skills.

Many life science careers utilize biological systems to produce commercially important biomaterials and biomolecules for use in agriculture, medicines, food and beverage processing, and industrial applications. Rural Georgia educators need support in life science career recognition, applicable hands-on teaching techniques, and access to supplies and equipment for their students.

Georgia Bio supports the state of Georgia to continue funding the Department of Education to advance Georgia BioEd’s Rural Teacher Training Initiative to strengthen Georgia’s life sciences workforce pipeline through classroom-to-career initiatives that align with industry needs.

Patient Access to Care:
Too many Georgians face barriers to accessing meaningful and timely care. In rural communities, many hospitals are struggling to keep their doors open. And throughout the state, even Georgians with coverage can face difficulties accessing specialty care or prescription drugs.

Georgia Bio supports patient access to innovative therapies and adequate provider networks through private and public insurance, including Medicaid, while enhancing plan transparency and encouraging competition among providers and insurers.

Establish a Georgia Rare Disease Advisory Council:

With over 7,000 known rare diseases, it is incredibly difficult for anyone to have an in-depth understanding of the entire rare community. Consequently, this lack of awareness contributes to some common difficulties that rare disease patients must face every day, such as delays in diagnosis, misdiagnosis, lack of treatment options, high drug costs, and limited access to medical specialists.

Rare Disease Advisory Councils help represent the needs of the entire rare disease community by giving patients, families, caregivers, and other stakeholders an opportunity to make formal recommendations to state leaders about the most important issue they face. Further, the membership of rare councils includes a variety of stakeholders that represent the entire rare community, including patients, caregivers, doctors, insurers, drug manufacturers, and researchers.

Georgia Bio supports the creation of a Georgia Rare Disease Advisory Council to address the needs of the rare disease community.

About Georgia Bio

Georgia Bio (GaBio), founded in 1989, is a non-profit, membership-based organization that promotes the interests and growth of the life sciences industry.  It is the state’s largest and most influential life sciences advocacy and business leadership organization which works to improve access to innovative technologies and grow Georgia’s life sciences economy. Members include companies, universities, research institutions, government groups and other industry associations involved in discovery and application of life sciences products and related services that improve the health and well-being of people throughout the world.

Georgia Bio’s mission is to advance the growth of Georgia’s life sciences industry and foster strategic partnerships that can create a healthier world. To accomplish this mission, GaBio conducts business and economic development activities; advocates on behalf of the industry on public policy matters; educates the public about the benefits of life sciences research and product development; and provides a network for the exchange of ideas, information and opportunities.

###

Georgia Life Sciences Weighs In on PBM and 340B Policy

October 5, 2026
Georgia Life Sciences has submitted written comments to the Georgia House Study Committee on Pharmacy Benefits Managers and Consumers’ Access to Prescription Medications, encouraging greater transparency, accountability, and a focus on measurable patient benefit across the prescription drug system. The comments address both pharmacy benefit manager practices and the federal 340B Drug Pricing Program, emphasizing the importance of understanding where prescription drug savings accrue and whether those savings ultimately benefit patients. The Study Committee continues its work this fall as it develops recommendations for the Georgia General Assembly. Read Georgia Life Sciences’ full comments →

Georgia Life Sciences Joins National Coalition Calling for PAHPA Reauthorization

September 22, 2026
Georgia Life Sciences (GLS) has joined more than 80 organizations from across industry, academia, public health and the biosecurity community in calling on congressional leaders to fully reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA) before the end of 2026. Led by the Johns Hopkins Center for Health Security, the coalition urged congressional leaders to advance a comprehensive reauthorization of PAHPA, the federal framework that supports the nation’s ability to prepare for and respond to public health emergencies and other health security threats. First enacted in 2006, PAHPA established and strengthened critical components of the nation’s health security infrastructure, including the Biomedical Advanced Research and Development Authority (BARDA). The law also supports public-private partnerships involved in the research, development, manufacturing and procurement of medical countermeasures, including vaccines, therapeutics and diagnostics. PAHPA’s authorization expired in 2023 and key provisions have since continued through short-term extensions. The coalition is calling for a comprehensive reauthorization that provides greater stability and ensures the nation’s preparedness infrastructure can continue adapting to emerging biological, infectious disease and other health security threats. For the life sciences industry, these programs are particularly important. Partnerships between government and industry can help move promising technologies from research through development and manufacturing while maintaining capabilities needed to respond quickly during an emergency. The Biotechnology Innovation Organization (BIO), also a signatory to the letter, has identified several priorities for reauthorization, including continued authorization of BARDA, the Strategic National Stockpile, Project BioShield and the Pandemic Influenza Program, as well as incentives supporting the development of medical countermeasures. Georgia Life Sciences is proud to join organizations across the country in supporting a strong and sustainable national framework for health security, preparedness and biomedical innovation. Read the coalition letter and view the full list of signatories.

Georgia Life Sciences Urges Protection of Patient Access as Georgia Implements Medicaid Changes

September 14, 2026
Georgia Life Sciences has submitted comments to the Georgia Department of Community Health (DCH) regarding the Georgia Pathways to Coverage program and implementation of new federal Medicaid requirements. As Georgia prepares for these changes, Georgia Life Sciences is urging state leaders to prioritize continuity of care and minimize unnecessary administrative barriers that could delay or disrupt access to medically necessary treatment . This is particularly important for Georgians living with serious, chronic, rare, and medically complex conditions who may rely on ongoing medications, diagnostics, therapies, medical technologies, specialty care, and coordinated treatment plans. Even temporary disruptions in coverage can interrupt care and create additional challenges for patients and families. In its comments, Georgia Life Sciences encouraged DCH to protect continuity of coverage during eligibility and redetermination processes, provide patients and caregivers with clear and timely information, minimize unnecessary administrative burdens, and establish appropriate safeguards when a coverage disruption could interrupt an established course of treatment. “As Georgia implements these new federal requirements, we want to ensure that patients remain at the center of the process,” said Maria Thacker Goethe, MPH, President & CEO of Georgia Life Sciences. “Administrative changes should not become barriers between patients and the care they need. Protecting continuity of care is particularly important for Georgians managing serious and complex health conditions.” Read Georgia Life Sciences’ full comments to DCH here.
MORE POSTS